Paclitaxel Serum Concentrations Linked to Severity of Neuropathy in Breast Cancer Patients

Video

This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, discusses a 60-patient study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

Henry was one of the coauthors of the study (abstract P6-11-03), which was presented during a poster session at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Across different studies, the highest incidence of left ventricular ejection fraction decrease was seen with trastuzumab/pertuzumab plus chemotherapy.

T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer

Russ Conroy
December 8th 2025
Article

Across different studies, the highest incidence of left ventricular ejection fraction decrease was seen with trastuzumab/pertuzumab plus chemotherapy.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Roman Fabbricatore
December 5th 2025
Article

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

Giredestrant Exhibits DFS Improvement in Early-Stage Breast Cancer

Roman Fabbricatore
November 18th 2025
Article

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications

Tim Cortese
November 13th 2025
Article

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.